Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epigenetic Health Benefits of Budesonide
NCT04342039Phase 4Active, not recruiting
- Sponsor
- University of British Columbia
- Start
- Jan 2021
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of EPI-EE in allergic rhinitis (AR) (2 arms), sponsored by University of British Columbia. Primary endpoint: Budesonide affect on allergic rhinitis plus allergen at 48 hours. Started Jan 2021; status: active, not recruiting.
02
Drugs
EPI-EE
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT04342039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04342039.